Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 87585 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Form number & name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(min./hour 60) 

78 ........ 57.602 Late Onset Sepsis/Meningitis Event Form: Data Table for Monthly Electronic Upload.300 6 6/60 

79 ........ 57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)— 

IT Initial Set up.

5,500 1 1,620/60 

57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)— 

IT Yearly Maintenance.

5,500 1 1,200/60 

57.700 Medication Safety-Digital Measure Reporting Plan (HYPO, HAKI, ORAE)— 

Infection Preventionist.

5,500 4 10/60 

80 ........ 57.701 Glycemic Control Module-HYPO Annual Survey ........................................... 10 1 180/60 

81 ........ 57.800 Billing Code Data: 837I Upload ..................................................................... 5,500 4 5/60 

82 ........ 57.801 External Validation Summary Report ............................................................. 20 2 15/60 

83 ........ 57.802 Bed Capacity-IT Initial Set Up ....................................................................... 25 1 20/60 

84 ........ 57.803 All Hazards ..................................................................................................... 540 365 5/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25552 Filed 11–1–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day–25–25AU; Docket No. CDC–2024– 

0088] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Risk factors, 

clinical course, presence and 

persistence of virus in various bodily 

fluids, and risk of sexual transmission 

among U.S. adults with Oropouche 

virus (OROV) disease. This study will 

assist in the response to this emerging 

virus by; identifying risk factors for 

infection to inform prevention guidance 

and messaging, informing recognition, 

diagnosis, follow-up care, and 

counseling of patients with OROV 

disease, and understanding risks of 

sexual transmission to inform 

prevention recommendations, especially 

for pregnant people and their partners, 

or those considering pregnancy. 

DATES: CDC must receive written 

comments on or before January 3, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0088 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Risk factors, clinical course, presence 

and persistence of virus in various 

bodily fluids, and risk of sexual 

transmission among U.S. adults with 

Oropouche virus (OROV) disease— 

New—National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 


lotter on DSK11XQN23PROD with NOTICES1
87586 Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 

Background and Brief Description 

Oropouche virus is an emerging virus 

in the Americas that is spread by the 

bite of midges and some species of 

mosquitoes. Infection with Oropouche 

virus generally causes a febrile illness, 

but more severe disease such as 

meningitis and hemorrhagic disease can 

occur. Beginning in late 2023, the 

geographic range of Oropouche virus 

has expanded, with over 10,000 cases 

from six countries reported in 2024 as 

of October 15. The first U.S. cases were 

reported in the summer of 2024, all 

among returning international travelers. 

This recent geographic expansion, along 

with reports of deaths among cases, 

vertical transmission leading to fetal 

loss and birth defects, and identification 

of live virus in semen raise concerns 

about the broader threat this virus 

represents to the United States. There 

are numerous gaps in our understanding 

of this emerging virus, including the 

urgent need to evaluate the possibility 

of sexual transmission to inform 

prevention recommendations, especially 

for pregnant people and their partners, 

or those considering pregnancy. 

The purpose of this investigation is to 

better define the risk factors, clinical 

course, viral shedding, and potential for 

sexual transmission among patients 

with Oropouche virus disease. 

Participants will be interviewed about 

their symptoms, medical and travel 

history, potential risk factors for 

infection, and sexual partners since 

becoming ill. They will be followed over 

time to see if their symptoms reoccur, 

which has been highlighted as a unique 

feature of Oropouche virus disease 

among similar viruses. They will also 

submit specimens of various bodily 

fluids over a 12-week period to be tested 

for Oropouche virus RNA. Lastly, sexual 

contacts of people who have been 

diagnosed with Oropouche virus disease 

will be interviewed to see if they 

experienced any symptoms consistent 

with Oropouche virus disease after 

these sexual encounters. Sexual contacts 

that report symptoms will be asked to 

have a blood sample collected and 

tested for evidence of Oropouche virus 

infection. 

The findings of this investigation will 

inform prevention guidance, improve 

clinical recognition and diagnosis, and 

prevent further illnesses of Oropouche 

virus disease. Preliminary results will 

be used immediately to inform agency 

response activities and prevention 

guidance to help people protect 

themselves from Oropouche virus 

disease. CDC requests Emergency OMB 

approval for an estimated 663 annual 

burden hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

General public ..................................... Baseline survey .................................. 200 1 30/60 100 

Follow-up clinical survey .................... 200 6 15/60 300 

Symptom Diary ................................... 200 6 10/60 200 

Contact tracing survey ....................... 100 1 15/60 25 

Sexual contact interview form ............ 150 1 15/60 38 

Total ............................................. ............................................................. ...................... .......................... .................... 663 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25553 Filed 11–1–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–25–0891; Docket No. CDC–2024– 

0086] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled World Trade Center (WTC) Health 

Program Enrollment, Appeals & 

Reimbursement. The WTC Health 

Program is a Federal limited benefit 

health care program providing medical 

monitoring and treatment benefits to 

eligible firefighters and related 

personnel, law enforcement officers, 

and rescue, recovery, and cleanup 

workers who responded to the 

September 11, 2001, attacks in New 

York City, at the Pentagon, and in 

Shanksville, Pennsylvania (responders), 

and to eligible persons who were 

present in the dust or dust cloud on 

September 11, 2001, or who worked, 

resided, or attended school, childcare, 

or adult daycare in the New York City 

disaster area (survivors). 

DATES: CDC must receive written 

comments on or before January 3, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0086 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments through 

the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 


lotter on DSK11XQN23PROD with NOTICES1